BioCardia Inc (NAS:BCDA)

Q3 2024 BioCardia Inc Earnings Call Transcript

Nov 13, 2024 / 09:30 PM GMT

Release Date Price: $2.35 (-2.08%)

Transcript 8-K10-Q

Key Points

Positve

BioCardia Inc (BCDA) has received FDA breakthrough designation for its lead autologous cardiac cell therapy for heart failure, which is also reimbursed by Medicare and Medicaid.
The company is conducting two active clinical trials for its cardiac cell therapy, with promising interim results showing improved survival and reduced major adverse cardiac events.
BioCardia Inc (BCDA) has secured FDA approval for its Morph DNA steerable introducer platform, which has potential applications in various clinical procedures.
The company successfully closed a $7.2 million public offering, ensuring compliance with Nasdaq's listing requirements and extending its financial runway.
Research and development expenses have decreased significantly, reflecting efficient management and completion of enrollment in the cardiac heart failure one trial.

Negative

Enrollment in the cardiac heart failure two trial has been delayed due to external factors such as hurricanes, impacting the company's timeline.
BioCardia Inc (BCDA) does not expect significant near-term revenues from its Morph DNA platform despite FDA approval.
The company faces challenges in the competitive market for electrophysiology products, which could impact the commercial success of its Morph DNA platform.
There is uncertainty regarding the outcome of regulatory consultations in Japan, which could affect the company's ability to commercialize its therapies in that market.
BioCardia Inc (BCDA) anticipates a moderate increase in cash burn over the coming year, which could strain financial resources if not managed carefully.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BCDA.OQ - BioCardia Inc
Q3 2024 BioCardia Inc Earnings Call
Nov 13, 2024 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon. Ladies and gentlemen, thank you for standing by.

Welcome to the Bio Cardia third quarter, 2024 financial results and business update conference call.

At this time, all participants are in a listen-only mode.

If you need assistance, please sign a conference specialist by pressing the star key followed by zero.

After today's presentation, there will be an opportunity to ask questions to ask a question. You may press star and then one using a Touchstone telephone.

Draw your questions. You may press star. Two participants of this call are advised that the audio of this conference call is being broadcast live over the internet and is also being recorded for playback purposes.

A

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.